Carbohydrate antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: A national cancer database study

Journal of the American College of Surgeons

Volumn 223, Issue 1, 2016, Pages 52-65

  Bergquist, John R ^a   Puig, Carlos A ^a   Shubert, Christopher R ^a   Groeschl, Ryan T ^a   Habermann, Elizabeth B ^a   Kendrick, Michael L ^a   Nagorney, David M ^a   Smoot, Rory L ^a   Farnell, Michael B ^a   Truty, Mark J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADULT; ADVERSE OUTCOME; AGE; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; FEMALE; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PERIOPERATIVE PERIOD; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; SYSTEMIC THERAPY; TREATMENT INDICATION; ADJUVANT RADIOTHERAPY; BLOOD; CANCER STAGING; CARCINOMA, PANCREATIC DUCTAL; FACTUAL DATABASE; FOLLOW UP; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PATHOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; CHEMOTHERAPY, ADJUVANT; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84961876852     PISSN: 10727515     EISSN: 18791190     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2016.02.009     Document Type: Article

References (67)

1. D. Parkin, F. Bray, and S. Devesa Cancer burden in the year 2000. The global picture Eur J Cancer 37 2001 4 66
2. L. Rahib, B.D. Smith, R. Aizenberg, and et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res 74 2014 2913 2921
3. M. Wagner, C. Redaelli, M. Lietz, and et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma Br J Surg 91 2004 586 594
4. K.Y. Bilimoria, D.J. Bentrem, C.Y. Ko, and et al. National failure to operate on early stage pancreatic cancer Ann Surg 246 2007 173 180
5. A.B. Cooper, C.W. Tzeng, and M.H. Katz Treatment of borderline resectable pancreatic cancer Curr Treat Options Oncol 14 2013 293 310
6. M.H. Katz, G.R. Varadhachary, J.B. Fleming, and et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation Ann Surg Oncol 17 2010 1794 1801
7. C. Galli, D. Basso, and M. Plebani CA 19-9: Handle with care Clin Chem Lab Med 51 2013 1369 1383
8. K.E. Poruk, M.A. Firpo, D.G. Adler, and S.J. Mulvihill Screening for pancreatic cancer Ann Surg 257 2013 17 26
9. R. Zubarik, S.R. Gordon, S.D. Lidofsky, and et al. Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study Gastrointest Endosc 74 2011 87 95
10. H. Koprowski, Z. Steplewski, K. Mitchell, and et al. Colorectal carcinoma antigens detected by hybridoma antibodies Somatic Cell Genet 5 1979 957 971
11. H. Koprowski, M. Herlyn, Z. Steplewski, and H.F. Sears Specific antigen in serum of patients with colon carcinoma Science 212 1981 53 55
12. R. Kannagi Carbohydrate antigen sialyl Lewis a-its pathophysiological significance and induction mechanism in cancer progression Chang Gung Med J 30 2007 189 209
13. T.F. Orntoft, E.M. Vestergaard, E. Holmes, and et al. Influence of Lewis alpha1-3/4-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels J Biol Chem 271 1996 32260 32268
14. L.C. Yu, Y.H. Yang, R.E. Broadberry, and et al. Correlation of a missense mutation in the human Secretor alpha 1,2-fucosyltransferase gene with the Lewis(a+b+) phenotype: a potential molecular basis for the weak Secretor allele (Sew) Biochem J 312 Pt 2 1995 329 332
15. S. Kawai, K. Suzuki, K. Nishio, and et al. Smoking and serum CA19-9 levels according to Lewis and secretor genotypes Int J Cancer 123 2008 2880 2884
16. H.D. Park, K.U. Park, J. Song, and et al. The relationship between Lewis/Secretor genotypes and serum carbohydrate antigen 19-9 levels in a Korean population Korean J Lab Med 30 2010 51 57
17. A.C. Berger, I.M. Meszoely, E. Ross, and et al. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma Ann Surg Oncol 11 2004 644 649
18. K. Miyazaki, K. Ohmori, M. Izawa, and et al. Loss of disialyl Lewis(a), the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulin-like lectin-7 (Siglec-7) associated with increased sialyl Lewis(a) expression on human colon cancers Cancer Res 64 2004 4498 4505
19. M. Sanchez, H. Gomes, and E.N. Marcus Elevated CA 19-9 levels in a patient with Mirizzi syndrome: case report South Med J 99 2006 160 163
20. C.R. Scoggins, D. Moore, K. Washington, and et al. Supra-elevated CA 19-9 in a benign hepatic cyst adenoma HPB (Oxford) 6 2004 43 44
21. R.A. Wolff Neoadjuvant therapy for resectable and borderline resectable adenocarcinoma of the pancreas Curr Drug Targets 13 2012 781 788
22. S.K. Maithel, S. Maloney, C. Winston, and et al. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma Ann Surg Onc 15 2008 3512 3520
23. A. Karachristos, N. Scarmeas, and J.P. Hoffman CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer J Gastrointest Surg 9 2005 1286 1292
24. J.G. Barton, J.P. Bois, M.G. Sarr, and et al. Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma J Gastrointest Surg 13 2009 2050 2058
25. U.K. Ballehaninna, and R.S. Chamberlain The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal J Gastrointest Oncol 3 2012 105 119
26. S. Dumitra, M.H. Jamal, J. Aboukhalil, and et al. Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score HPB (Oxford) 15 2013 1002 1009
27. T. Frebourg, E. Bercoff, N. Manchon, and et al. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients Cancer 62 1988 2287 2290
28. K.S. Goonetilleke, and A.K. Siriwardena Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer Eur J Surg Oncol 33 2007 266 270
29. W. Hartwig, O. Strobel, U. Hinz, and et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy Ann Surg Oncol 20 2013 2188 2196
30. S. Hata, Y. Sakamoto, Y. Yamamoto, and et al. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer Ann Surg Oncol 19 2012 636 641
31. N. Kondo, Y. Murakami, K. Uemura, and et al. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer Ann Surg Oncol 17 2010 2321 2329
32. F. Tian, H.E. Appert, J. Myles, and J.M. Howard Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma Ann Surg 215 1992 350 355
33. W. Steinberg The clinical utility of the CA 19-9 tumor-associated antigen Am J Gastroenterol 85 1990 350 355
34. C.P. Raut, D.B. Evans, C.H. Crane, and et al. Neoadjuvant therapy for resectable pancreatic cancer Surg Oncol Clin North Am 13 2004 639 661 ix
35. M.V. Raval, K.Y. Bilimoria, A.K. Stewart, and et al. Using the NCDB for cancer care improvement: An introduction to available quality assessment tools J Surg Oncol 99 2009 488 490
36. C.W.D. Tzeng, H.S.T. Cao, J.E. Lee, and et al. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival J Gastrointest Surg 18 2014 16 25
37. J.P. Neoptolemos, D.D. Stocken, H. Friess, and et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 2004 1200 1210
38. M.H. Kalser, and S.S. Ellenberg Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection Arch Surg 120 1985 899 903
39. C.W. Tzeng, J.B. Fleming, J.E. Lee, and et al. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy Ann Surg Oncol 19 2012 2045 2053
40. F. Faisal, H.-L. Tsai, A. Blackford, and et al. Longer course of induction chemotherapy followed by chemoradiation favors better survival outcomes for patients with locally advanced pancreatic cancer Am J Clin Oncol 39 2016 18 26
41. H. Oettle, P. Neuhaus, A. Hochhaus, and et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial JAMA 310 2013 1473 1481
42. K.Y. Bilimoria, D.J. Bentrem, C.Y. Ko, and et al. Multimodality therapy for pancreatic cancer in the U.S: utilization, outcomes, and the effect of hospital volume Cancer 110 2007 1227 1234
43. G.M. Heestand, J.D. Murphy, and A.M. Lowy Approach to patients with pancreatic cancer without detectable metastases J Clin Oncol 33 2015 1770 1778
44. T. Schnelldorfer, A.L. Ware, M.G. Sarr, and et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 247 2008 456 462
45. J.P. Neoptolemos, D.D. Stocken, C. Bassi, and et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 304 2010 1073 1081
46. R. Kannagi, M. Izawa, T. Koike, and et al. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis Cancer Sci 95 2004 377 384
47. R. Kannagi Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer Glycoconj J 14 1997 577 584
48. T. Koike, N. Kimura, K. Miyazaki, and et al. Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates Proc Natl Acad Sci USA 101 2004 8132 8137
49. E.M. Vestergaard, H.O. Hein, H. Meyer, and et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population Clin Chem 45 1999 54 61
50. S. Hakomori Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer Biochem Biophys Acta Gen Subj 1473 1999 247 266
51. T. Conroy, F. Desseigne, M. Ychou, and et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
52. J.M. Sutton, and D.E. Abbott Neoadjuvant therapy for pancreas cancer: past lessons and future therapies World J Gastroenterol 20 2014 15564 15579
53. C. Belli, S. Cereda, S. Anand, and M. Reni Neoadjuvant therapy in resectable pancreatic cancer: A critical review Cancer Treat Rev 39 2013 518 524
54. E.V. Tsvetkova, and T.R. Asmis Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here? Curr Oncol 21 2014 e650 657
55. F. Polistina, G. Di Natale, G. Bonciarelli, and et al. Neoadjuvant strategies for pancreatic cancer World J Gastroenterol 20 2014 9374 9383
56. J.D. Allendorf, M. Lauerman, A. Bill, and et al. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival J Gastrointest Surg 12 2008 91 100
57. B.A. Boone, J. Steve, A.M. Krasinskas, and et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer J Surg Oncol 108 2013 236 241
58. K.K. Christians, S. Tsai, A. Mahmoud, and et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist 19 2014 266 274
59. D.E. Abbott, C.-W.D. Tzeng, R.P. Merkow, and et al. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma Ann Surg Oncol 20 Suppl 3 2013 S500 S508
60. P.F. Peddi, and A. Wang-Gillam Successful resection after neoadjuvant therapy in pancreatic adenocarcinoma J Natl Compr Canc Netw 10 2012 1330 1334
61. J.E. Barone Pancreaticoduodenectomy for presumed pancreatic cancer Surg Oncol 17 2008 139 144
62. Bergquist JR, Puig CA, Shubert CR, Truty MJ. "Preoperative CA 19-9 does not correlate with locoregional tumor cell burden in resectable pancreatic adenocarcinoma". Presented at the 2015 Society for Surgical Oncology Annual Cancer Symposium, Houston, TX. March 25-28, 2015.
63. M.K. Accordino, J.D. Wright, S. Vasan, and et al. Serum tumor marker use in patients with advanced solid tumors J Oncol Pract 12 2016 65 66
64. B.A. Boone, J. Steve, M.S. Zenati, and et al. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma Ann Surg Oncol 21 2014 4351 4358
65. E.G. Brown, R.J. Canter, and R.J. Bold Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma J Surg Oncol 111 2015 293 298
66. T.M. Bauer, B.F. El-Rayes, X. Li, and et al. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials Cancer 119 2013 285 292
67. G.Y. Yang, N.K. Malik, R. Chandrasekhar, and et al. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer J Gastrointest Oncol 4 2013 361 369